Skip Navigation


Mol. Hum. Reprod. Advance Access originally published online on April 22, 2008
Molecular Human Reproduction 2008 14(5):259-268; doi:10.1093/molehr/gan019
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
14/5/259    most recent
gan019v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Van Langendonckt, A.
Right arrow Articles by Groothuis, P. G.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Van Langendonckt, A.
Right arrow Articles by Groothuis, P. G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Antiangiogenic and vascular-disrupting agents in endometriosis: pitfalls and promises

Anne Van Langendonckt1, Jacques Donnez1,4, Sylvie Defrère1, Gerard A.J. Dunselman2 and Patrick G. Groothuis3

1Department of Gynaecology, Université Catholique de Louvain, Avenue Hippocrate 10, 1200 Brussels, Belgium 2 Research Institute GROW, Department of Obstetrics and Gynaecology, University Hospital Maastricht, Maastricht, The Netherlands 3Organon Biosciences, Schering-Plough, P.O. Box 20 5340, BH, Oss, The Netherlands

4 Correspondence address. Tel: +32-2-764-95-01; Fax: +32-2-764-95-07; E-mail: donnez{at}gyne.ucl.be

It is widely known that angiogenesis plays a key role in endometriotic lesion formation and development. Antiangiogenic treatments aimed at inhibiting new vessel formation have proven efficient in experimental models. However, as antiangiogenic strategies do not target pre-existing pericyte-protected vessels, they require chronic administration and are likely to be beneficial for early-stage disease only or to prevent recurrence after surgery. Moreover, they may have detrimental effects on reproductive function. Vascular-disrupting agents (VDAs) have emerged as a promising new tool for the treatment of tumors. VDAs target established blood vessels, resulting in tumor ischemia and necrosis. These agents may therefore be more efficient against advanced disease. Two major types of VDAs are being developed for cancer: ligand-directed VDAs using antibodies, peptides and growth factors to deliver toxic effectors to tumor endothelium; and small-molecule VDAs exploiting physiological differences between tumor and normal endothelium to induce acute vascular shutdown. The ongoing evolution in genomics and proteomics is revolutionizing the discovery of novel endothelial markers. Several studies suggest that the vasculature of endometriotic lesions may have particular pathophysiological properties, which could be exploited for the development of selective VDAs. The aim of this review is to explore the merits and limitations of vascular therapy for the treatment of endometriosis.

Key words: endometriosis/angiogenesis/vascular-disrupting agent/antiangiogenic therapy/chronic inflammation

Submitted on February 12, 2008; resubmitted on April 9, 2008; accepted on April 15, 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.